AltumView Systems
AltumView is a Vancouver AI company founded in 2016. It develops a smart sensor for applications such as senior care, security, and telehealth. The sensor monitors the activity of people such as seniors, collect health statistics, and notify caregivers when emergencies are detected, while preserving privacy. It has been in the markets of Canada, Japan, China, and Taiwan for one year. The second-generation sensor will be released in early 2021, which recently won the CES 2021 Innovation Award Honoree. The company has raised several rounds of angel funds, and is seeking new capital to scale up manufacturing, marketing, and R&D.
Presenter: Jie Liang, President and CEO
Read More
BresoTEC
BresoTEC has developed a proprietary acoustic and movement-based AI analysis platform that transforms the precision of a sleep laboratory in to a simple, cordless technology for home use. BresoTEC has completed development and will begin clinical trials early in the new year. Use of funds raised are for scale up of marketing, selling and regulatory manufacturing costs for the US market, development of the second version of the BresoDX home sleep test and scaling costs.
Presenter: Peter Bloch, CEO
Read More
Curiato
Curiato is a digital health platform that is leveraging biosensing and AI to deliver patient data and insights directly from the surface of the bed to power an ecosystem of applications such as pressure injuries, heart failure, infectious disease, burns, patient safety and more. One device, multiple clinical software applications. Curiato is post revenue with successful clinical pilots, publications and Health Canada licensed. Curiatio is raising Series A capital to support US market entry, sales & marketing, and creation of additional clinical software applications.
Presenter: Moazam Khan, Co-Founder & CEO
Read More
Huron Digital Pathology
With a first-of-its-kind, AI-enabled image search engine called Lagotto, Huron Digital Pathology is revolutionizing how pathologists access the vast knowledge contained in the world’s pathology reports, hospital records, and clinical data, to drive efficiency and reduce diagnostic error. We just gained our first high profile customer for Lagotto in the US and are beginning to generate recurring software revenue. We are actively engaging with large hospitals and institutions keen to benefit from our solution. We are raising a Series A round to scale our sales efforts, expand our product portfolio and achieve regulatory approvals.
Presenter: Patrick Myles, Chief Executive Officer
Read More
KA Imaging Inc
KA Imaging has created color x-ray (Reveal™)which allows for soft tissue and bone separation resulting in better patient outcomes. Reveal™, has received USA FDA 510(k) clearance and Health Canada approval and the company is focusing on commercialisation. KA is raising $25M USD for commercialization infrastructure (sales, service and applications), marketing the hardware-as-a-service revenue model and AI development.
Presenter: Amol Karnick, President & CEO
Read More
My Intelligent Machines
My Intelligent Machines (MIMs), based in Montreal, is a leader in artificial intelligence applied to life sciences. We provide Biopharma and Agtech companies with augmented intelligence systems enabling life scientists working in this space to model patients, cells, tissues or farm animals to develop more efficient and personalized treatments and agro-products. We are closing our Series A of 5M$ by Jan 2021. The proceeds will be used for the scaling phase, to consolidate our leadership in Canada, USA & Europe & team growth.
Presenter: Sarah Jenna, CEO
Read More
Mobio Interactive
Mobio Interactive is a revenue-generating digital therapeutics company that develops and commercializes clinically validated and objectively quantified software to prevent, measure and treat mental illness. Mobio’s recent progress includes completion of a clinical trial with cancer patients, demonstrating equivalent effect sizes on psychological wellbeing from the DTx Am Mindfulness as compared to group psychotherapy. Mobio is raising Series A capital to support clinical trials, IP protection, payor & partner negotiations, regulatory approval, and DTx sales.
Presenter: Bechara Saab, CEO
Read More
Neurovine
Neurovine is a Series A stage prescription digital health platform that uses AI and connected wearables to improve brain recovery after a concussion. The proceeds will allow Neurovine to complete the second clinical trial and the regulatory process and to launch the product with Canadian physiotherapists and sports medicine physicians who have established billing codes.
Hear more from this company during the Early Technology Showcase.
Presenter: Ashleigh Kennedy, Founder
Read More
Nightingale.ai
Nightingale.ai is in development of a computer vision-based mobile application for end-to-end automation of physiotherapy management of patients post total hip and knee replacement. This self-assessment and treatment planning tool enable remote personalized care in a cost-effective manner. The company is currently in pre-seed stage. The proceeds from seed financing will be used on creating the prototype of the first-of-its-kind computer vision-based functional tests and treatment planning, conducting pre-clinical trials, and covering essential developer compensation.
Hear more from this company during the Early Technology Showcase.
Presenter: Sameer Chunara, Co-founder and CEO
Read More
Oncoustics
Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Oncoustics applies AI to raw ultrasound signals from readily available handheld ultrasound devices to rapidly differentiate healthy versus diseased tissues. Oncoustics is a clinical-stage company with partnerships with several ultrasound OEMs, and FDA pre-sub and trials this year. Oncoustics is raising Series A capital to bring the first product to market (FDA clearance), and continue growing the data library for new indications, as well as grow the team.
Presenter: Ahmed El Kaffas, Founder
Read More
Perceiv
Perceiv is an AI-based digital biomarkers company specializing in the field of precision medicine. We are dedicated to reducing risks for patients and making clinical trials more cost-effective through advanced machine learning algorithms. We have secured $360K (USD) in non-dilutive public funding and we are seeking $2M (USD) in dilutive investment. These proceeds would go into making key hires (scientists, developers, and business development staff), operationalizing and commercializing our Alzheimer’s solution (product launch), supporting partnerships for data access with pharmaceutical companies and hospitals, and further improving our platform to accelerate new product development, and support the development new products (cardiovascular diseases).
Presenter: Christian Dansereau, CEO
Read More
PROTXX
PROTXX enhances care, outcomes, and healthcare economics for patients living with neuro-disruptive (e.g. concussion, stroke) and neuro-degenerative (e.g. multiple sclerosis, Parkinson’s disease) medical conditions. Our precision health platform integrates innovations in non-invasive wearable physiological sensors and machine learning classification of neurosensory and neuromotor impairments, replacing complex clinical equipment and time-consuming tests with easier-to-use, lower-cost, in-clinic and remote precision patient assessments. At the core of the PROTXX platform is the company’s “phybrata” sensor, a tiny, non-invasive device worn behind the ear that is able to classify, quantify, and monitor impairments to the major neurophysiological systems in the body.
Presenter: John Ralston, CEO and Founder
Read More
Replica Analytics
Replica Analytics develops data synthesis technology. This allows data simulators to be created – these are models that can be used to generate new data while retaining the statistical properties and patterns in the original data. A key use case of data simulators is to provide rapid access to clinical data within the enterprise, and to augment small studies (i.e., use 50% of the target recruitment to simulate the remaining 50%). Data augmentation can change the economics of clinical studies by allowing the same conclusions to be drawn from smaller datasets.
Hear more from this company during the Early Technology Showcase.
Presenter: Khaled El Emam, Co-founder and Director
Read More
